The UK and US have secured a major commercial pact that will ensure no duties on UK drug exports entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise spending on medicines through the public health system. This commitment ensures that tariffs on these crucial products will be held at nothing for a timeframe of the next three years.
This deal follows recent statements to hike import taxes on patented pharmaceutical products, with figures floated as high as 100%.
"This deal with the UK reinforces the international landscape for innovative medicines and introduces long-overdue balance to U.S.–U.K. medicine commerce," an announcement declared.
Commercial Significance
Medicines are one of the UK's largest exports to the America, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to the third quarter, the UK exported medicines totaling billions to the US. This amount accounted for a significant portion of all goods exports in that period.
"This deal secures work, boosts capital expenditure and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Specific British Pledges
The pact includes several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded 20%.
Recent Tensions
The pact takes place against a protracted tension between the sector and the UK government over spending levels and regulatory access.
The disagreement were heightened by arguments that American customers were paying a premium for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.